Business
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
1st of two presentations with results from Phase 2b study of neflamapimod at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference Data demonstrates neflamapimod treatment led to significant reductions in plasma glial fibrillary acidic protein (GFAP), a key marker of neuroinflammation-associated neurodegeneration, and increased beta amyloid (A) 42/40 ratio in DLB Correlation of the effects of neflamapimod on plasma GFAP with positive treatment response, as assessed by CDR-SB, support
About this update from Cervomed Inc.
[{"type":"image","alt":"CervoMed Inc.","displaySize":"","headline":null,"caption":"CervoMed Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/59afd81325b0c8128225f052847e0aa6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YRNF9gHnIhIY0CXM.LMRnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/59afd81325b0c8128225f052847e0aa6","width":300,"height":93}},"lazy":false},{"type":"text","content":"1st of two presentations with results from Phase 2b study of neflamapimod at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference","length":146,"tagName":"p"},{"type":"text","content":"Data demonstrates neflamapimod treatment led to significant reductions in plasma glial fibrillary acidic protein (GFAP), a key marker of neuroinflammation-associated neurodegeneration, and increased beta amyloid (A) 42/40 ratio in DLB","length":234,"tagName":"p"},{"type":"text","content":"Correlation of the effects of neflamapimod on plasma GFAP with positive treatment response, as assessed by CDR-SB, support neflamapimod mechanism of action and suggest it may act on underlying disease ","length":200,"tagName":"p"},{"type":"text","content":"BOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, has shared new data from the Phase 2b RewinD-LB trial demonstrating neflamapimod treatment led to a significant reduction in the widely used neurodegeneration biomarker plasma GFAP and an increase in A42/40 ratio, an inverse marker of neuroinflammation and amyloidogenesis. In addition, neflamapimod treatment showed a trend towards reducing plasma neurofilament light (NfL) chains levels.","length":555,"tagName":"p"},{"type":"text","content":"These data were presented on December 1, 2025, at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Diego, California. A second presentation will take place in an oral late-breaking session at the conference on December 4th, 2025, in which Dr. John-Paul Taylor, MBBS, MRCPsych, PhD, Professor of Translational Dementia Research at Newcastle University, will provide the clinical outcome results from RewinD-LB.","length":437,"tagName":"p"},{"type":"text","content":"“...